Good afternoon, everyone and welcome to the webcast of ATEC’s Third Quarter Financial Results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the SEC. During this call, you may hear the company refer to reported amounts, which are in accordance with U.S. GAAP as well as non-GAAP or pro forma measures. Reconciliations of non-GAAP measures to U.S. GAAP can be found in the supplemental financial tables included in the press release, which identify and quantify all excluded items and provide management’s view of why this information is useful to investors. Leading today’s call will be ATEC’s Chairman and CEO, Pat Miles and CFO, Todd Koning. Now, I will turn the call over to Pat Miles.

Thanks very much, Michelle and thanks everybody for joining the Q3 2022 financial results call. As you would expect, there will be some forward-looking statements. So if you would review the small print at your leisure that would be great. So celebrating my fifth year here and recollecting back to the first full year of 2018, we finished with U.S. revenue that approximated $84 million. It’s nice five years later to be generating $90 million for the quarter, which is a 43% year-over-year growth rate. And the thesis clearly is working. So what we are doing is scaling top line growth toward positive adjusted EBITDA in 2023, advancing lateral sophistication with innovation, improving the predictability and reproducibility of core elements of spine surgery, reflecting our information-based competitive advantage and extending EOS’ influence while leveraging new hospital access. So taking a quick look at the Q3 2022 scorecard, I do believe it to be a validation of what we’re doing. So 43% year-over-year growth as stated. It’s really 53% in terms of surgical revenue growth. And so the growth is very strong. It’s our 14th consecutive quarter of greater than 20% U.S. revenue growth, excluding the 11% in the pandemic-ridden Q2 2020, 32% year-over-year growth in procedure volume, 15% year-over-year growth in average revenue per case, $11 million in EOS revenue, with a significant opportunity pipeline up 45% year-over-year, and we’ll get into the blended average of product categories per case with that and the 2.3 and continues to grow. And so what I want to do is just give a little bit of a strategic view with regard to our commitments and kind of why we’re doing what we’re doing. And these are the things that create value in the company. Ultimately, they get categorized into three commitments. And it’s creating clinical distinction, which we love to move the field of spine surgery forward, and that compels surgeons. Surgeons want to do better work, and they are compelled by clinical distinction. And then also focusing on elevating the sales channel. And so just jumping right into that is clinical distinction is driven by an investment thesis around asset allocation to create clinical predictability. And as stated, the momentum really has demonstrated buy-in to that. And our focus, and we’ve really kind of had the opportunity at numerous meetings this quarter to display this, is really a focus on lateral surgery, and we’ll get into a little bit more of that. We are super proud of what’s going on, on the SafeOp front; we will get into that, the first really of many expandable implants that come. We are bolstering ACDF with a new cervical plate insignia. And then also expanding the ecosystem of AIX, which is the Alpha Informatix ecosystem, with an app called Via. And so we will talk a little bit about that as well. But our intention, to be hugely subtle, is to dominate lateral surgery. And there is great internal competence at ATEC in lateral surgery. The group here really popularized it. And so our know-how on that front is significant. And you may ask, why focus on lateral surgery? And our belief is that it’s better. And the literature is profoundly compelling. Less blood loss, shorter hospital stays, shorter return to normal activity. It truly is the most coveted market in spine and the one that continues to grow. And so if you are going to dominate lateral surgery, a foundational requirement is neuromonitoring. And there’s no way around it. And having been at this for north of 20 years, you’re not getting around being a player in lateral surgery without neuromonitoring. It’s really why we focus so much effort and garnered so much expertise in this area. The group here internally is phenomenal, and our experience with regard to automating EMGs and automating SSEPs really kind of has been foundational. And so SafeOp is the only neuromonitoring system that provides both location and health information of the neuroplexus. And really, the most concerning part of lateral surgery is the risk of femoral nerve injury. And so to be able to locate where it is and to understand what its health is, is of significant value. It is actionable information that drives surgeon decision-making. And the history of spine has been wrought with subjective rules, and another one in lateral surgery is one that says, Hey, I’ve got to get in and out of the surgery in 20 minutes. Meaning, the exposure that I make in the psoas has to be no more than 20 minutes. That stuff goes on until someone creates an objective measure, and that’s what we did with SafeOp. It’s proprietary to us, and we can’t be more excited about the effect that automated SSEPs is having on lateral surgery. And so remain profoundly bullish on PTP. Super excited about what’s going on, on that front. Super excited about the momentum. A big reason why traditional lateral did not become ubiquitous was that from a single position it didn’t serve all three goals of spine surgery and so only in the prone position. So PTP can serve predictably decompression, stabilization and alignment, which are the goals of spine surgery. So PTP has enabled surgeons to address multiple different types of spine pathologies that explicitly achieves the goals from a single position. It is increasingly utilized in complex surgery and is early in the reflection within the peer-reviewed publications. And so the reason why people are coming to Carlsbad is because of PTP. And there’s a boatload of them coming and they continue to come, and we’ve had a big year in terms of surgeons coming to Carlsbad to learn PTP. So one of the ways that we talk about sophistication around here is really, I think, through a quote that in essence says sophistication is in relation to the number of distinctions one draws to a subject. Our intent is to dominate lateral surgery. In so doing, we have recently begun to release LTP, which is a lateral transpsoas surgery really built from the ground up. It enables surgeons who have traditionally applied lateral surgery in the lateral position and prefer to approach the bottom level, which is L5-S1, from an ALIF perspective. I think one of the easiest ways to kind of start to think through PTP and LTP is I would think of it as that which is driven by the pathology. And so the more complex pathology, where there requires a direct decompression and stabilization, I would think PTP. More of a degenerative population, which is short segment but may include 5-1, for a surgeon who wants to do it through an ALIF, I would think LTP. But the beauty is back to the sophistication thing. Our ability to provide both platforms that accommodate the surgeon’s interest is really what we’re after. So we’ve taken all the learnings from PTP and developed a patient positioner that facilitates lateral surgery and a more midline ALIF access to L5-S1. It’s amazing that we are in this day and age and people are talking about the commoditization of spine surgery, but we’re still taping patients to beds. And so we believe that the addition of the patient positioner, a specifically designed retractor system, the integration of SafeOp and just an entire procedure built from the ground up is going to be a welcome evolution in the field of lateral transpsoas surgery. So I cannot be more excited about that either. So speaking of applied learnings, we have also launched our first of many expandable interbody devices. This is a posterior approach expandable, first and foremost, to assure lordotic correction is accomplished from the back in the prone position. It anchors PTP by providing a medialized posterior approach at L5-S1. In expected ATEC fashion, the medialized posterior procedure includes specific InVictus cortical screw design, coupled with an elegant retractor system and an expandable interbody device. And so now we have solutions both from an LTP via ALIF and a PTP via the medialized posterior approach for both lateral techniques. So transferring now to really the Informatix element and just a little bit about Via. Our interest is in integrating our multiple Informatix elements. We’ve recently released an app called Via. What it does is it quantifies the alignment parameters, and it will enable broad EOS image access for integration into our interoperative solutions. And so, it’s another tool whereby we can distribute EOS-related information. More to come, but wanted to provide a little bit of a view in the many ways we will deliver information that will improve decision making. So I want to talk a little bit about EOS. EOS continues to go quite well. We believe that the value of EOS is unmatched. We believe that a standing, weight-bearing, biplanar, non-magnified image, we have the makings of a spine alignment standard. Alignment remains the greatest correlative to a successful, durable, long-term outcome. And it doesn’t matter in short segment or in long segment surgery. It is profoundly valuable in terms of the ability to understand how a spine need be aligned. There is an old quip in spine surgery that 100% of spine surgeons are deformity surgeons. They either create them or they fix them. Many truths are clearly said in jest, but the revision risk for malaligned patients is 10x that of a properly aligned patient. The SRS, who is really the authority when it comes to spinal alignment, are big fans of EOS. During a recent meeting in Sweden, Larry Lenke, previous SRS President and famed deformity surgeon, polled the audience, and 70% of the surgeons in the audience at SRS owned an EOS machine. Another 30% raised their hands that they had more than one. So we see this as the society that influences these types of surgeons. And to me, as the SRS goes, oftentimes the rest of the spine community goes. And so the question really becomes is, all right, what do you do from here? And really, our work has really been defined and described and it’s ongoing. And what it’s about is integrating and designing feature sets that can integrate into ATEC procedures. And so providing automated alignment reports that enable expedient surgical planning, generating data to drive pre-op and inter-op rod bending, understanding bone density measure to provide surgeons an understanding of underlying bone quality, not to mention all the back office work that’s going on that’s assembling a predictive analytics platform and a platform that ultimately will enable us to gain some operational efficiencies as well. Something else that occurred to us as we were thinking about the quarter and so often we utilize things like hey, we are just getting going and I think a lot of people utilize that nomenclature to fill space. But to us, it’s very apparent as we demonstrate that the foundational elements of our platforms are very relevant, well beyond lateral surgery. And so just wanted to provide an example of a field that we are working on so imagine an idiopathic scoliosis patient with a rotational deformity, that’s kind of right in the middle of what companies like us focus on. It would be profoundly advantageous to understand the apex of this deformity via EOS. So you start to think about what the value of our foundational technology is and you think, gosh, EOS will provide great value in that patient type. And then you start to ask yourself, what’s the reciprocal alignment – what reciprocal alignment would be gained through direct vertebral rotation via the InVictus DVR system, direct vertebral rotation system. And then you say, gosh, positioning her or the patient in a patient position to assist the surgeon and maximizing the correction, that would be quite valuable and then assuring the neurologic safety of the correction with facilitated MEPs as they are derotating the spine. So I think so often people look at these foundational elements as unique or independent, when the reality is the application for these elements will be reflected in future types of applications. So when we say we’re just getting started, we genuinely mean it. We’re literally just getting started. And so that’s just a little bit about the whole clinical distinction and would love to give you a couple of objective measures with regard to compelling surgeon adoption. And so we have more surgeon users, 22% growth in surgeon user base year-over-year. As we talked a bit, the aggregate products per procedure is growing. It was at 2.3% in Q3 of ‘22. And the volume of surgeons coming through our surgeon education group and coming through ATEC has been significant, and that was right around 150. And so not much to add to this slide, other than the fact that what we’re seeing is just continued growth in our thesis. And we look at this as a proxy for are people buying into the very clinical thesis that we’re putting forward. And when they use more of the proposed products, then the likelihood for them buying into this thesis is much better. Love what’s going on in the sales channel. Love what’s going on, Dave Sponsel’s lead with regard to the field force and the continued evolution. In those areas that we have established sales agencies, we enjoy a 46% year-over-year revenue growth. And for us, that’s a proxy of same-store sales and the stickiness of what’s going on. The market share is always a bit of a challenge, but we believe ourselves to be a 3% holder, and I always think that means we have 97% to go, and that we’re a 5% holder in those markets that we participate in. We still have uncovered geographies, so, in the aggregate probably a 3%; in those geographies that we participate in, more like a 5%. And as I think everybody appreciates, the sales force is very much shaping up. However, it is the perpetual build and the perpetual place of improvement. And so, anyway, just wanted to give you a few kind of background dynamics of what’s going on with the company. And probably best that I turn it over to Todd at this point.

Alright. Well, thanks, Pat. Appreciate it and good afternoon, everybody. We appreciate you joining us on the call today. So I’ll begin with revenue. Third quarter total revenue was $90 million, reflecting 43% growth over the prior year and a 7% increase compared to the second quarter. The $90 million in revenue is comprised of $79 million in surgical revenue and $11 million of EOS revenue. Now that we have fully anniversaried the close of the EOS transaction, what we used to refer to as organic revenue will now be referred to as surgical revenue. The third quarter surgical revenue of $79 million increased 53% compared to the prior year period. Procedural volume grew 32% year-over-year as surgeon adoption continued to expand. The number of surgeon users increased 22% compared to last year, reflecting the strong level of training activity we have consistently seen over the last year. Additionally, much of our growth is coming from established sales agencies with at least one year of tenure, and that cohort achieved 46% growth in the quarter, demonstrating durable sales growth from our most tenured agents. Average revenue per case expanded 15% year-over-year as revenue mix continues to shift toward procedures with more products per case and procedures with greater complexity. As a reminder, the average revenue per lateral procedure is about double our overall average, and lateral-related revenue continues to grow meaningfully faster than surgical revenue overall. While lateral-related revenue again contributed the most to our growth, revenue related to biologics, CLIF and ALIF also grew significantly in the quarter. EOS revenue in the third quarter was $11 million, flat compared to Q3 of 2021 on a reported basis and up 7% in constant currency. Results reflect the timing of capital deliveries and installations in the period. Experience is increasingly helping us to better manage the complexity of deliveries and installations and also continue to make nice progress with the integration. We have achieved 45% growth in the opportunity pipeline year-over-year and are on track with platform innovation initiatives. Continuing through the remainder of the P&L, third quarter non-GAAP gross margin was 71%, down 130 basis points compared to the prior year. Increased EOS service costs, as we address the backlog of service calls created during the COVID-19 pandemic, contributed 90 basis points of pressure year-over-year. Another 60 basis points of gross margin pressure was related to an increase in our biologics attach rate, which comes at a meaningfully lower gross margin profile than our overall business. Our expectation is that the margin headwinds outlined above will persist throughout the year. Operating expense in the third quarter demonstrated leverage, while thoughtful investments in the long-term sector-leading growth continued. Third quarter non-GAAP R&D was $10 million and approximately 12% of sales, 100 basis points lower than the prior year. The increase on an absolute dollar basis was driven by continued investment to support organic portfolio expansion and the advancement of the EOS platform. Non-GAAP SG&A was $67 million and approximately 75% of sales in the third quarter, compared to $52 million and approximately 84% of sales in the prior year period. We delivered 860 basis points of improvement while continuing to invest in the expansion and training of the ATEC sales network, surgeon education and support for the increasing size and sophistication of the company. Total non-GAAP operating expenses amounted to $78 million and approximately 87% of sales in the third quarter, compared to $60 million and 96% of sales in the prior year period, delivering a total of 960 basis points of operating leverage year-over-year. I’d also like to highlight that we achieved 200 basis points of operating leverage sequentially. That is an early testament to the leverage we are expecting to deliver as our business scales. Adjusted EBITDA was a loss of $6 million and approximately 7% of sales in the third quarter, compared to a $10 million loss and 16% of sales in the prior year. The improvement of 870 basis points as a percent of sales was driven by 960 basis points of operating expense leverage, which was partially offset by gross margin. Sequentially, adjusted EBITDA improved $2 million on a revenue step-up of $6 million and resulting in 290 basis points of improvement. As sales growth leverage across our business, we expect an adjusted EBITDA loss for the full year 2022 of approximately $28 million, or about 8% of sales, relative to approximately 12% of sales in 2021. And this will position us well to deliver the breakeven adjusted EBITDA that we are committed to for the full year 2023. Turning to the balance sheet, we ended the third quarter with $106 million in cash. Operating cash use improved relative to last quarter and totaled $24 million. Roughly half of that sequential improvement was driven by lower instruments, inventory and PP&E spend. Approximately $2 million improvement was related to reduced litigation spend and the balance by improved EBITDA and working capital. We continue to expect full year 2022 cash use to meaningfully improve relative to last year, consistent with our long-term plan. Debt at carrying value is $370 million, which includes $316 million of a convertible debt and a drawdown of $35 million from the $50 million revolving credit facility that we closed in the third quarter. Now turning to our outlook for the full year 2022, in line with 40% full year growth rate that we previewed in conjunction with the prerelease of the third quarter financial results, we now expect full year 2022 total revenue to approximate $340 million, which, as a reminder, compares to guidance of $325 million previously. Updated guidance includes the following. We now expect full year 2022 surgical revenue to approximate $294 million, compared to $277 million previously. Updated expectations reflect growth of 39% compared to 2021, which contemplates strong performance in the third quarter and continued momentum into the fourth quarter. We now expect EOS revenue of approximately $46 million for the full year 2022, compared to $48 million previously. Updated guidance for EOS reflects the timing and complexity of installations and deliveries from our order book as the EOS business becomes more U.S. market concentrated. Let me share how our expectations for procedure volume growth and the expansion of our average revenue per surgery support updated ATEC surgical revenue guidance. With surgeon adoption expanding and surgeon utilization increasing, we have achieved strong procedure volume growth throughout the year, including 32% in the third quarter. As a result, we now expect procedure volumes to grow at low-20s rate for the full year, compared to the high-teens percent rate we anticipated previously. Average revenue per surgery grows as our procedural mix shifts towards procedures that require more products per surgery, like PTP and LTP, and towards surgeries with greater complexity, all of which feature higher revenue per procedure than our overall average. The strength of the growth in revenue per surgery year-to-date, including a 15% growth rate in the third quarter, drives our new expectation for a low double-digit rate of expansion for the full year, compared to the high single-digit percent rate that we expected previously. As most of you know, our guidance philosophy is to be thoughtful and prudent about how we set expectations by putting numbers out there that we believe we can achieve and have a reasonable opportunity to exceed. In closing, the third quarter marked the introduction of significant innovation. We showcased LTP at NASS, launched our first expandable interbody cage and introduced our medialized posterior approach. Our sector-leading growth continues to validate our procedural thesis and reinforces that clinical distinction is what ultimately compels surgeon adoption. We also demonstrated how revenue growth will enable us to scale the business and begin to deliver operating leverage. In short, third quarter performance was another step toward the achievement of our long-term objectives. As you may expect, we have another active IR calendar over the next few months, and I hope to connect with many of you in person. With that, I will turn it over to Pat.

Thanks much, Todd. I think that we have gone deep in this before, but literally, our focus is how do we continue to earn market share through lateral sophistication, how do we garner more by earning the respect and confidence of the surgeons to garner more of their practice, and that’s the halo effect and nice to have new products launched within that category. We will continue to focus on the sales channel and continue to improve from now until as far as the eye can see. We are in the process of getting international off the ground, in a small way. And I would tell you that we haven’t even begun to see the influence of EOS in the meaningful way that we expect it in the years to come. And so we love the acquisition and love the long view associated with our opportunity in that space. So as we talked about at our Investor Day, our focus is $555 million in 2025, which would be an adjusted EBITDA of $80 million and really focused on just the disciplined investment on the walk. And so our opportunity to address the need for predictability and reproducibility is massive. The spine market is massive, and it’s ours for the taking. So we believe that spine needs ATEC. And with that, we will turn it back to the operator. Michelle, are you there?

Yes, okay. The first question comes from Matthew O’Brien with Piper Sandler.

Hey, this is Phil on for Matt. Thank you for taking my questions and Pat, congrats on 5 years. Another impressive quarter in terms of procedural volumes and this is despite longer vacation cycles that some of your competition pointed out. I was wondering if you could provide color as to why you were a bit more insulated from that dynamic compared to your peers. And I guess the real question I am getting at here is, could you have grown quicker in a more normalized environment? Thank you.

Yes. One, appreciate the whole 5-year congrats. We love what we are building here. And hopefully, we will do another Investor Day at some point and get people here. I think the enthusiasm for the spine space is palpable and we love what we are doing. I don’t think that we are insulated from the dynamics of what is going on. We are also still what I would consider a smaller player in this space. And so some of the macro demographics – like, we are earning share. And so we are earning share at a great rate. And what’s earning share is doing and making investments in some of the foundational technology that I was talking about earlier, like patient positioners and retractors and things that are super meaningful to surgeons.

Great. Thanks.

The next question comes from Young Li with Jefferies.

Alright. Great. Thanks guys for taking the question. I also want to extend my congrats to Pat for 5 years here. It’s certainly been a fun ride. So, I guess good to see the continued momentum in the business. You have a nice cadence of new product launches this year and more to come next year. You are on track for record surgeon training this year, with a pretty strong track record of contribution from the previously trained cohorts. And it seems like this momentum should carry over in the forward period. Maybe there are some tough comps. But any early comments you can make on the sustainability of your growth momentum in the upcoming period?

Thank you, Li. This is Todd. And we appreciate the question. And I guess, as I kind of think about the metrics you shared, I think one of the things that we talked about on our Investor Day was how surgeon training is a great leading indicator for surgeon adoption. And the level of interest that we are seeing coming through the facility is incredibly strong, as you mentioned. I think just approximately 150 surgeons came through again in the quarter. And I think we also know that as surgeons adopt our technology, and as we see it in particular in PTP, they not only begin to use the approach in more complex surgeries, but ultimately, as we earn their trust and confidence, we gain a greater share of their overall business.

Alright. Great. Appreciate it. Looking forward to seeing you guys.

Yes. Thanks Young.

Your next question comes from Brooks O’Neil with Lake Street Capital Markets.

Thank you. It was nice to see you at NASS. And I am just curious if you could talk just a little bit about the response you got from surgeons to the stuff you were presenting and talking about at the Spine Show.

Yes. Brooks thanks. It’s good to hear you. I think it’s one of the things where I think people have great expectation with regard to our continued transformation of the lateral space. I think when your CMO is Luiz Pimenta and the other surgeons who are around this that have the level of technical aptitude in the lateral space, I think that there is a big expectation and a lot of enthusiasm around what we are doing laterally. And I think that that was very, very well received. I think the other thing that was exciting was just the volume of surgeons who see the vision on the EOS front. And just when you start to think through all of the opportunities that present themselves with regard to the information that comes out of that machine, it is significant. The other huge validation becomes when the SRS, the Scoliosis Research Society, has such a predominance of users and, again, is a forward view of what’s to come from a mainstream spine practice dynamic. And so I would say kind of the things that really jumped out at me is just the momentum of the company is palpable, and I believe we are making investments in the right places.

Your next question comes from Drew Ranieri with Morgan Stanley.

Hi. Thanks for taking the question and Pat, congratulations on 5 years, and I hope more to come. But my question, I am going to pick on Todd, and I have a follow-up for you, Pat. But Todd, just on – I think I heard you with leverage comments that you improved leverage about 200 basis points. But I was hoping you might be able to drill in a bit more on really what the cash burn was, your operating cash burn was, in the quarter. I might have missed it, but it would be great if you can make any comments about that and really kind of remind us about your confidence for improving leverage into next year and becoming EBITDA profitable, or breakeven, for ‘23.

Thanks Drew. Happy to do that and appreciate the opportunity. Our operating cash burn, our free cash burn, was $24 million in the quarter. So, if you kind of remember what our commitment has been is to do tens of millions of dollars better than we did last year. We did $142 million of cash burn last year, free cash burn. And really, the commentary implies about $122 million of free cash burn as kind of a ceiling for us. And so the $24 million free cash burn here in the quarter, I think is very much in line with being able to deliver on that commitment. And so I think we feel good about where that landed. I think it’s certainly within our expectations and sets us up for a good Q4 on the free cash burn standpoint there. I think sequentially, Q2, our free cash burn was $40 million. Really, half the improvement was a reduction in sets and inventory in PP&E. We saw a reduction in litigation spend sequentially. And then the balance is really an improvement in adjusted EBITDA and net working capital. So, I think on the free cash burn perspective, we are right where we expected to be and set us up nice for a good finish. On the adjusted EBITDA line, we had a negative $6 million of adjusted EBITDA in the period and ultimately feel good about that. I think ultimately, the commitment again is to deliver flat adjusted EBITDA from 2021. So, that implies a $28 million number here in the full year. And so ultimately, as you kind of look at what we delivered in Q1, which was $10 million in Q2, $8 million – and now, $6 million here in Q3. I think what’s notable there is that really implies a $3 million improvement in Q4, a $3 million adjusted EBITDA loss in Q4. And again, I think that kind of trajectory sets us up very nicely going into next year and achieving our commitment of being adjusted EBITDA breakeven into next year. And I guess, finally, I would just kind of say we saw a $6 million step-up Q2 to Q3 in revenue and dropped through about $2 million of that in adjusted EBITDA improvement. And again, I think that kind of all feels good and makes sense. So, at the end of the day, year-over-year adjusted EBITDA of negative $6 million is about 7% of sales and improved 870 basis points over the prior year Q3. And really, this is a good quarter from a comparison standpoint year-over-year because it’s really the first quarter we have fully comped out the EOS acquisition. So, it gives you a good sense for where we are at and where we are heading.

Your next question comes from the line of Josh Jennings with Cowen.

Hi. This is Eric on for Josh. Thanks for taking the questions. Just thinking about LTP, with the launch kind of just around the corner, could you talk about the learnings that you will be able to take from you experienced launching and finding commercial success with PTP that you will be applying to the launch of LTP? Thank you.

Yes. Thanks Eric for the question. I have to get comfortable because it’s a subject that I absolutely adore, is the whole lateral surgery one. And I would tell you probably the first kind of undeniable truth that we have learned is just the ability to manage the patient within a patient positioner and to put the surgeon in a position to ultimately effectuate surgery in a much more elegant and efficient manner. And so you think about you are trying to do orthogonal surgery. The ability to utilize a patient positioner to make sure that you are truly in an orthogonal position, the patient is in an orthogonal position, compared to taking them to the bed, I would tell you that is diametrically different. And I think that we have been awarded by our investment with PTP into a patient positioner, because now what we can do is apply that learning to LTP. The other element is designing for the respective procedure. And so from a retractor perspective and then the integration of neurophysiology, there is really kind of a significant experience with SafeOp that the sales force has enjoyed that will absolutely integrate directly into what we are doing with LTP. And so I think that the sales force is used to what we are doing with regard to patient positioners and kind of the integrated components. And so I think where we will have a tailwind is within the sales force that has already been successful with people in terms of transforming them into PTP users and then picking up surgeons who want to continue to evolve into more predictability around what we are doing from an LTP perspective. The other place is, at L5-S1, a lot of – most surgeons still require an access surgeon. And so one way that will evolve is we will do general or vascular surgeon access courses at the company. And so again, a benefit of the patient positioner is that it puts you in a position to get more of a midline type of an ALIF at 5-1. And so just the ability to launch our whole ALIF retractor system with our LTP patient positioner avails really the opportunity to train both the vascular general surgeon with the spine surgeon, such that if you want to stay in the lateral position and go L3 to S1, your ability to do that through a lateral approach at 4-5 and 3-4 and then do a 5-1 ALIF and let the general surgeon do the exposure would be something that we would expect to be a common application of this position and procedure. So, probably more than you care to hear, but at least hopefully a little color.

That makes a lot of sense. Thank you for the question.

Your next question comes from Caitlin Cronin with Canaccord Genuity.

Hi, this is Caitlin on behalf of Kyle Rose. I have a couple of quick questions. Can you provide the U.S.-OUS split for EOS? Also, when do you expect to launch the Via app? Thanks.

On the EOS component, we haven’t been explicit about the revenue split. I mean what we have, Caitlin, said is, as we continue to grow the EOS business, it’s going to become more U.S.-centric. We are walking away from kind of non-strategic countries outside the U.S. and really kind of focusing our efforts. So, you will see more of a U.S. footprint as we grow this business over the coming years.

Yes. I was just going to draft off of that comment. It will also further the predictability associated with our performance, I think year-over-year. There is a lot of economies around the world that EOS would previously sell into that, candidly, didn’t facilitate our collective interest. And so again, I think we are a different company now, meaning EOS, and our ability to be more focused, as Todd said, into the States as well as into the strategic countries of our interest is going to be reflective of where the density of the business is. As it relates to Via, it is rolling out now, and it’s rolling out and being used, again, to quantify parameters, corrective parameters, in deformity. But the great thing is it’s the beginnings of another conduit into the operating room that we will utilize for a multitude of different reasons, be it tracking inventory, be it tracking doing charge sheets from an operational perspective, all the way through pulling down EOS images and preoperative planning elements and some of the rod-bending parameters that ultimately will integrate into new experience. So, our thrill for these tools is significant.

Your next question comes from David Saxon with Needham & Company.

Hi good afternoon guys and thanks for taking the questions. My question, I guess you have talked in the past about how Alphatec is underexposed from a geographic perspective in the U.S. So, just wondering with the competitor going through a merger and ATEC clearly outperforming the rest of spine, are you seeing opportunities to bring on new sales partners to build out your footprint, or maybe that comes later in the LRP or perhaps in the next LRP? Thanks so much.

I would say that we are always in the hunt. And I think a big part of the hunt for us is the shared interest in a long-term commitment. The last thing we want is transactional people. And with all of the money that we have invested in the technological advancement under the auspices of clinical distinction, we expect a heck of a lot out of the people who ultimately carry the lines, and they have got to be people who are committed to the long term and committed to us.

Great. Thank you.

Your next question comes from Jason Wittes with Loop Capital.

Hi. Thanks for taking the question. Appreciate the detail you gave and especially on the underlying drivers of guidance. And if I look at kind of what you have introduced most recently, quite a bit again, but it seems like the expandable cage in biologics should be an easy layup in terms of just improving revenue per case. Is that the right way of thinking? Whereas LTP, it sounds like, I don’t know what type of trajectory we should be anticipating for that, but I would love to get a little more understanding if you could.

Yes. Jason, I will start and then I will let Todd fix my mistakes. There is no such thing as a layup in this business. You know the fact of the matter is – your point is a really good one in that what we found is guys would use our TLIF retractor and our screw system, and then because we didn’t have expandable technology they would use somebody else’s expandable device. And so those types of things get rectified immediately, and those are the things that we are super excited about. And as I noted in my commentary, it’s really the first of many expandable devices. And so we will have other expandable devices this year that we are enthusiastic about walking through what we call the alpha or the verification cycle of the performance of the devices. But you will see many more. And one of the great values of an expandable device is really the control alignment, or lordosis. And so again, things that you don’t care about, but are hugely meaningful, is when you put something in a device and you want to control the spine, you have to release the spine. And one of the great things about PTP is you release the back of the spine and the front of the spine, and it provides you the ability to really be very sophisticated with regard to how you drive alignment. And so we think the relevance of the expandable device is going to be significant based upon not only the fact that, gosh, we have an expandable device, but we have techniques that ultimately accommodate maximizing their meaning.

And Jason, I think you are spot-on in terms of how that plays out in our financials. Both the expandable interbody and biologics end up being a tailwind to revenue per procedure. Because in the biologics case, especially as we are getting a lot of growth and, in particular, from our synthetic biologics that we recently launched, we are getting more attach rate. And ultimately, that biologics attach rate is happening in procedures that we kind of have had in the past. And so we are seeing another product category being added to an existing procedure run rate. The same on expandables, and that may come through in the fact that expandable has a higher ASP. And so maybe it’s replacing a static cage that we get today or in the case that Pat mentioned, maybe we are getting the expandable today where we weren’t in the past and so both of those are certainly revenue tailwinds to the revenue per procedure and additions to products per case.

And just really quick on LTP, can we assume first kind of – obviously, it’s too early to see how big this is going to be. But in terms of adoption and even types of surgeons, does it look like PTP, or does it look different, or how are you thinking about it?

That’s a good question. It’s one of those things where it’s like we have been so focused on kind of the verification that everything is functioning like it’s supposed to. We look at lateral as such a growth center of our business. We see this as really kind of a long walk. Like, what we are going to do is – it’s interesting. We have a lot of the degenerative elements built and ready to plug in. And so my expectation is this is going to be a bit of a walk with regard to we are going to do degenerative cases, as I said. I think it’s most applicable in L3 to S1, where somebody wants to do ALIF at 5-1. And so that’s why I think about it as such a degenerative tool. But there is also going to be, as we continue – like, next year we will come out with a corpectomy device. And so you will start to see again expanding dollars and expanding complexity in our LTP portfolio. But I see it a bit like you said, I think in terms of just the slow walk on the LTP front out of the gate. And we are going to have some training courses with some luminaries in the field of lateral surgery. And so that will, I think create some momentum. But it’s like all of these things. They just take time to get the people around them and get the people trained and comfortable to make for momentum.

Very helpful and also congratulations on 5 years. Look forward to congratulating you at a $1 billion revenue, which I think comes before 10 years, so anyway thank you very much.

That will be the real celebration. I didn’t intend to speak about me. I was more excited just about the fact that 5 years ago, we were at an $83 million run rate, or $84 million, for the year, and now we are doing it quarterly. And you just love the continued momentum. Well, thanks very much for your interest in ATEC and very much appreciate the questions and look forward to talking to everybody next quarter. Thanks much.